BeatIt-MV Therapy for Minimally Verbal Autistic Adults
Trial Summary
What is the purpose of this trial?
The present study aims to adapt and evaluate the feasibility of the BeatIt-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be currently receiving other treatment for depression.
What data supports the effectiveness of the treatment BeatIt-MV for minimally verbal autistic adults?
Behavioral Activation, a component of the treatment, is widely accepted for treating depression in other populations and is being adapted for autistic adults, suggesting potential benefits. Additionally, app-based meditation, another behavioral intervention, has shown effectiveness in reducing depression symptoms in autistic adults, indicating that similar behavioral strategies may be beneficial.12345
Is BeatIt-MV Therapy safe for humans?
How is the BeatIt-MV treatment different from other treatments for minimally verbal autistic adults?
BeatIt-MV is unique because it adapts behavioral activation, a therapy typically used for depression, to help autistic adults by focusing on increasing engagement in meaningful activities and reducing feelings of being 'stuck'. This approach is novel for autism as it targets both physical and emotional aspects to improve overall well-being.12101112
Research Team
Vanessa Bal, PhD
Principal Investigator
Rutgers University - New Brunswick
Eligibility Criteria
This trial is for minimally verbal adults over 18 with Autism Spectrum Disorder and depression, who have a support person and can travel to Rutgers University in New Jersey or New York. It's not suitable for those without these specific conditions or support.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention Development
Adapting the BeatIt-2 manual to consider specific needs of minimally verbal autistic adults
Treatment
Participants, along with support persons, will complete 12 weekly sessions of the BeatIt-MV intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BeatIt-MV (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
Dr. Jonathan Holloway
Rutgers, The State University of New Jersey
Chief Executive Officer since 2020
PhD in History from Yale University
Dr. Brian Strom
Rutgers, The State University of New Jersey
Chief Medical Officer since 2014
MD from Rutgers New Jersey Medical School